These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. Van Woert MH; Rosenbaum D; Howieson J; Bowers MB N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457 [TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of serotonin precursors in postanoxic action myoclonus. De Léan J; Richardson JC; Hornykiewicz O Neurology; 1976 Sep; 26(9):863-8. PubMed ID: 1084968 [TBL] [Abstract][Full Text] [Related]
4. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Pranzatelli MR Arch Neurol; 1994 Jun; 51(6):605-17. PubMed ID: 7515228 [TBL] [Abstract][Full Text] [Related]
5. Post-hypoxic intention myoclonus treated with 5-hydroxy-tryptophan and an extracerebral decarboxylase inhibitor. Magnussen I; Dupont E; Engbaek F; de Fine Olivarius B Acta Neurol Scand; 1978 Apr; 57(4):289-94. PubMed ID: 307327 [TBL] [Abstract][Full Text] [Related]
6. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Van Woert MH; Sethy VH Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720 [TBL] [Abstract][Full Text] [Related]
8. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity. Giménez-Roldán S; Mateo D; Muradas V; De Yebenes JG Clin Neuropharmacol; 1988 Apr; 11(2):151-60. PubMed ID: 2454156 [TBL] [Abstract][Full Text] [Related]
9. [Utilization of levo-5-hydroxytryptophan in post-anoxic myoclonus]. Rascol A; Guiraud-Chaumeil B; Laboucarie J; Montastruc JL; El-Hage W Therapie; 1978; 33(5):623-8. PubMed ID: 311085 [No Abstract] [Full Text] [Related]
10. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Growdon JH; Young RR; Shahani BT Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988 [TBL] [Abstract][Full Text] [Related]
12. Biochemistry and therapeutics of posthypoxic myoclonus. Van Woert MH; Rosenbaum D; Chung EY Adv Neurol; 1986; 43():171-81. PubMed ID: 2418644 [No Abstract] [Full Text] [Related]
13. Effect of L-5HTP and drugs acting on serotonin metabolism in various myoclonic syndromes. Avanzini G; Bossi L; Caraceni T; Consolazione A; Franceschetti S; Negri S; Parati E Monogr Neural Sci; 1980; 5():142-52. PubMed ID: 6976509 [TBL] [Abstract][Full Text] [Related]
14. Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder. Chadwick D; Hallett M; Jenner P; Marsden CD Adv Neurol; 1986; 43():183-90. PubMed ID: 2418645 [No Abstract] [Full Text] [Related]
15. The serotonin hypothesis of myoclonus from the perspective of neuronal rhythmicity. Welsh JP; Placantonakis DG; Warsetsky SI; Marquez RG; Bernstein L; Aicher SA Adv Neurol; 2002; 89():307-29. PubMed ID: 11968457 [TBL] [Abstract][Full Text] [Related]
16. Manipulation of brain serotonin in the treatment of myoclonus. Chadwick D; Jenner P; Harris R; Reynolds EH; Marsden CD Lancet; 1975 Sep; 2(7932):434-5. PubMed ID: 51240 [TBL] [Abstract][Full Text] [Related]
17. Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice. Menon MK; Vivonia CA Eur J Pharmacol; 1981 Jul; 73(2-3):155-61. PubMed ID: 6118280 [TBL] [Abstract][Full Text] [Related]